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Background: The aim of this review is to discuss the role of aspirin for various conditions 
in women.
Methods: A nonsystematic review of articles published on PubMed® that examines the role 
of aspirin in women.
Results: Aspirin is associated with a significant reduction of stroke risk in women, which may 
be linked to age. However, despite this evidence, underutilization of aspirin in eligible women is 
reported. In women of reproductive age, it may also have a role to play in reducing early-onset 
preeclampsia and intrauterine growth restriction, and in the prevention of recurrent miscarriage 
in women with antiphospholipid antibodies; it may also reduce cardiovascular risk in associated 
systemic conditions such as lupus. Aspirin may reduce colorectal cancer risk in women, but its 
role in breast cancer warrants further data from controlled trials.
Conclusions: The risk–benefit threshold for aspirin use in women has been established for 
several conditions. Reasons why women are less likely to be prescribed aspirin have not been 
established, but the overall underuse of aspirin in women needs to be addressed.
Keywords: CVD, cancer, menopause, preeclampsia
Introduction
Aspirin has been available for over a century,1 and to date, over 100 randomized clini-
cal trials (RCTs) have established its efficacy and safety in men and women for the 
prevention of vascular conditions including acute myocardial infarction (MI), ischemic 
stroke, and peripheral arterial disease.2 RCTs have also shown that aspirin reduces the 
risk of colorectal cancer recurrence in high-risk subjects,3,4 while observational studies 
have associated a decreased risk of colorectal adenomas with regular aspirin use.5 A 
recently published, 20-year follow-up of randomized trials also found that low-dose 
aspirin reduced the incidence and mortality due to colorectal cancer in patients at no 
apparent increased risk for this malignancy.6 Aspirin may also have a beneficial role 
in the prevention of breast, prostate, lung, stomach, and esophageal cancers.7 Among 
women, aspirin may provide additional benefits in individuals at risk of preeclampsia, 
as was first postulated by Wallenburg et al8 in 1986 and found in a number of RCTs 
thereafter,9–11 and in postmenopausal individuals with or at risk of osteoporosis, rheu-
matoid arthritis, or breast cancer.12
Despite the compelling evidence that low-dose aspirin reduces morbidity and 
mortality in patients with cardiovascular disease (CVD), and numerous guidelines 
recommending its use,13–15 many eligible patients, especially women, are not receiving 
aspirin for this indication.16–18 Underutilization of aspirin may contribute to  worsening 
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morbidity, mortality, and health-related quality-of-life 
outcomes associated with vascular conditions in women 
compared with men.18 The Women’s Health Initiative 
 Observational Study (WHIOS), for example, which exam-
ined 8928 postmenopausal women with CVD, found that 
only 46% were taking aspirin. After 6.5 years of follow-up, 
however, adjusted aspirin use was associated with a signifi-
cantly lower all-cause mortality (hazard ratio [HR]: 0.86; 
P = 0.04) and cardiovascular-related mortality (HR: 0.75; 
P = 0.01) in those women taking aspirin.17 In addition to 
recommendations regarding the use of aspirin for the pre-
vention of CVD and associated complications, numerous 
guidelines also recommend low-dose aspirin for women 
at risk of preeclampsia;19–21 but again, there is considerable 
variation in its use for this indication.22
Aims and methods
The aim of this review is to discuss key issues in the use 
of aspirin for various conditions in women. A literature 
search was performed in Medline (PubMed®) using the title/
abstract search terms “aspirin AND cardiovascular AND 
women” (n = 343), “aspirin AND women’s health study” 
(n = 29), “aspirin AND preeclampsia” (n = 14), “aspirin 
AND antiphospholipid syndrome” (n = 16), and “aspirin AND 
cancer AND women” (n = 88). Reviewed articles were limited 
to English-language publications, clinical trials, and meta-
analyses, published within the last 5 years. All publications 
were manually searched. Articles of particular relevance 
known to the authors (including those earlier than 2005) have 
also been included. Although this approach may have intro-
duced some bias, it ensured that key data published before 
2005 were also included where relevant, such as the aspirin 
trials in CVD, but the focus of the article was the discussion 
of relatively recent data in women.
Cardiovascular disease
According to the American Heart Association, CVD was 
the cause of death in 432,709 US females in 2006, which 
was nearly twice that observed for death from all forms of 
cancer in women (N = 269,819).23 Since 1984, the number 
of CVD deaths for females has exceeded those for males in 
the US.23 The high incidence of CVD death among women 
has resulted in considerable interest in preventive interven-
tions that have been evaluated specifically in women, and 
there is also increasing awareness among women about 
the impact of CVD, particularly in older women.24,25 Key 
studies providing data on the role for aspirin in prevent-
ing CVD include the Women’s Health study (WHS), 
The Nurses’ Health Study (NHS), the WHIOS, and the 
Antithrombotic Trialists’ (ATT) Collaboration.17,26–29
The WHS, a double-blind RCT, evaluated the benefits of 
aspirin in the primary prevention of CVD in 39,876 appar-
ently healthy women health professionals. During a follow-up 
of around 10 years, 477 first major cardiovascular events 
were confirmed in the aspirin group compared with 522 in 
the placebo group. While this represented a nonsignificant 
trend toward lower risk of major events associated with CVD 
by 9% (relative risk [RR]: 0.91, 95% confidence interval 
[CI]: 0.80–1.03; P = 0.13) with aspirin in the overall group, 
analysis by age indicated that aspirin significantly reduced 
major events in women aged $ 65 years (RR: 0.74, 95% CI: 
0.59–0.92] in women aged $ 65 years vs (RR: 1.01, 95% 
CI: 0.81–1.26 in women aged 45–54 years). There was also 
a 34% reduction in the risk of MI in women aged $ 65 years 
(RR: 0.66, 95% CI: 0.44–0.97; P = 0.04). In addition, women 
taking aspirin experienced an overall 17% decrease in the risk 
of stroke (RR: 0.83, 95% CI: 0.69–0.99; P = 0.04), mostly 
due to significant reductions in ischemic stroke (RR: 0.76, 
95% CI: 0.63–0.93; P = 0.009). The RR for stroke reduction 
was comparable across all age groups.26
The NHS – a prospective study of 87,678 healthy female 
nurses in the age range 34–65 years and free of diagnosed 
CHD, stroke, and cancer at baseline – evaluated the associa-
tion between regular aspirin use and the risk of a first MI and 
other cardiovascular events over 6 years. In this study, the use 
of 1–6 aspirin tablets per week was associated with a 32% 
reduced risk of a first MI among women (RR: 0.68, 95% 
CI: 0.52–0.89; P = 0.005).27 Long-term, 24-year follow-up 
of this study showed that low-to-moderate doses of aspirin 
are associated with a 25% lower risk of all-cause mortality 
(RR: 0.75, 95% CI: 0.71–0.81) and a 38% reduced risk of 
CVD death (RR: 0.62, 95% CI: 0.55–0.71); these benefits 
were significant in older women and those with cardiac risk 
factors.28 The WHIOS – an observational study to evaluate 
the relationship between aspirin use (81 or 325 mg) and 
clinical outcomes among postmenopausal women with 
stable CVD – found that aspirin use was associated with 
significantly lower risk of all-cause mortality, specifically 
cardiovascular mortality, among postmenopausal women 
with stable CVD.17
Data from some of these key trials have been included 
in meta-analyses. The ATT Collaboration29 was a meta-
analysis of individual participant data on serious vascular 
events (MI, stroke, or vascular death) and major bleeds 
in six primary prevention trials (95,000 individuals at low 
average risk [∼50,000 were women], 660,000 person-years, 
International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
153
Aspirin in women’s health
 3554  serious vascular events) and 16 secondary prevention 
trials (17,000 individuals at high average risk, 43,000 person-
years, 3306 serious vascular events) that compared long-
term aspirin vs control. Among women, the RR for primary 
prevention of a major coronary event was 0.95 (95% CI: 
0.77–1.17); for ischemic stroke, 0.77 (95% CI: 0.59–0.99); 
and for a serious vascular event, 0.88 (95% CI: 0.76–1.01). 
In the secondary prevention trials among women, the RR for 
risk reduction for a major coronary event was 0.73 (95% CI: 
0.51–1.03); for ischemic stroke, 0.91 (95% CI: 0.52–1.57); 
and for a serious vascular event, 0.81 (95% CI: 0.64–1.02). 
These findings clearly show that low-dose aspirin has an 
important role to play in the prevention of stroke, particu-
larly in older women. This is important, as age-related stroke 
incidence is likely to increase dramatically in women com-
pared with men over the next 40 years.30 Stroke may also be 
linked (albeit rarely) to multiple pregnancies, eclampsia, the 
postpartum period, and migraine.31
A number of cardiovascular studies have established 
the benefit–risk profile of aspirin use in a range of low-, 
medium- and high-risk patients, and in those with diabetes. 
The absolute benefit of treatment vs major bleeding risk in 
1000 patients treated per year is illustrated in Figure 1,32 
which also indicates the position of the WHS26 and in low-risk 
patients with diabetes enrolled in the Japanese Primary Pre-
vention of Atherosclerosis with Aspirin for Diabetes (JPAD) 
study.33 The vascular events avoided in women enrolled in 
the WHS vs major bleeds associated with aspirin treatment 
is in the bottom left-hand corner of the figure; this is largely 
due to the nonsignificant reduction of major cardiovascular 
events in this trial, but does not illustrate the benefits in 
terms of stroke reduction, where the threshold will be more 
favorable.26 Largely as a result of the primary outcome of 
the WHS, the benefit–risk threshold and consequently the 
numbers needed to treat (NNT) to prevent one cardiovascular 
event is higher in women than in men when data are pooled in 
meta-analyses. In a meta-analysis of 95,456 subjects (51,342 
women) from cardiovascular trials, the NNT to prevent one 
cardiovascular event was 333 for women and 270 men based 
on a mean follow-up of 6.4 years.34
Cost-effectiveness of CVD 
prophylaxis with aspirin in women
Cost analyses in women are few, and are usually restricted 
to those that include sex as a subgroup. In general, these cost 
analyses have shown that aspirin is cost-effective in older 
women.35 In one analysis, which predicted the number of 
cardiovascular events prevented with treatment, quality-
adjusted life-years and cost over a 10-year period using a 
standard model, aspirin was found to be cost-effective as 
primary prevention in women aged . 65 years with high 
cardiovascular risk (10-year cardiovascular risk . 10%) and 
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Figure 1 The absolute benefit (in terms of vascular events avoided/1000 treated/year) vs risks (major bleeds/1000 treated/year) associated with aspirin treatment in the key 
cardiovascular trials enrolling low-, medium-, and high-risk patients. Adapted with permission from the American College of Chest Physicians. Patrono C, et al. Platelet-active 
drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–264S.
Abbreviations: BDT, British Doctors’ Trial; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, 
Physician’s Health Study; PPP, Primary Prevention Project; SAPAT, Swedish Angina Pectoris Aspirin Trial; TPT, Thrombosis Prevention Trial; WHS, Women’s Health Study.32
International Journal of Women’s Health 2011:3submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
154
Verheugt and Bolte
in women aged . 75 years with moderate cardiovascular risk 
(10-year cardiovascular risk . 15%).36
Findings from single trials and meta-analyses have 
yielded similar results. One cost analysis of aspirin for 
primary prevention of cardiovascular events based on the 
findings from a single trial indicated a favorable cost–utility 
ratio for older women with moderate cardiovascular risk.37 
Similar findings were observed when the ATT Collaboration 
meta-analysis data29 were included in a model.38
Guideline recommendations  
for CVD prevention in women
Based on findings from trials in women, there are now spe-
cific guidelines recommending the use of aspirin, mainly in 
stroke prevention and in high-risk women. The US Preventive 
Services Task Force (USPSTF) calculated the risk threshold 
(ie, the potential benefit of a reduction in ischemic strokes 
outweighs the potential harm of an increase in gastrointestinal 
[GI] hemorrhage) for aspirin use in stroke primary prevention 
at a risk level of 1%–20%.15 For women aged 55–59 years, 
the 10-year stroke risk is 3%, and the benefits of stroke 
prevention outweigh the risk of a GI bleed; this increases to 
8% in women aged 60–69 years and to 11% in women aged 
70–79 years. The USPSTF guidelines have been endorsed by 
a panel of experts from the American Diabetes Association, 
the American Heart Association, and the American College 
of Cardiology Foundation.
The AHA’s Effectiveness-Based Guidelines for the Pre-
vention of Cardiovascular Disease in Women 2011 Update39 
specifies that aspirin 75–325 mg/day is recommended in 
high-risk women with CHD and is reasonable in women with 
diabetes unless contraindicated; aspirin 81 mg/day or 100 mg 
every other day can be considered in women aged $ 65 years, 
if blood pressure is controlled and benefits in terms of isch-
emic stroke and MI prevention are likely to outweigh the risk 
of GI bleeding and hemorrhagic stroke, and it appears cost-
effective in women $ 65 years with moderate-severe CVD 
risk. Aspirin is recommended in women aged , 65 years, 
when benefit for ischemic stroke prevention is likely to 
outweigh adverse effects of therapy. Several guidelines also 
recommend aspirin for the prevention of stroke in women. 
Low-dose aspirin is recommended in women aged . 45 years 
(or , 65 years) who are not at increased risk for intracerebral 
hemorrhage and who have good GI tolerance.14,40 A number 
of other guidelines, including European guidelines, recom-
mend the use of aspirin in patients with established CVD and 
in asymptomatic individuals at high risk of CVD, but do not 
specify different approaches for women.41
Some studies have observed that women have greater 
residual platelet activity after high-dose aspirin compared 
with men treated with a lower dose of aspirin, suggesting 
that female patients may benefit from higher maintenance 
dosages or the use of alternative antiplatelet medications.42–44 
Findings from the ATT Collaboration, however, show that the 
reduction in risk of major cardiovascular events is similar for 
men and women at similar doses, and thus, platelet reactivity 
may not justify differential dosing.29
The expanding role of aspirin  
in obstetric conditions
Preeclampsia
Preeclampsia is a potentially fatal pregnancy-specific hyper-
tensive syndrome affecting around 2%–8% of pregnancies.45 
For the unborn child, it is linked to poor intrauterine growth, 
prematurity, and sometimes death,10,45 and among mothers 
can lead to a spectrum of complications including eclampsia, 
stroke, (pulmonary) edema, and retinal problems. Preeclamp-
sia/eclampsia is responsible for 10%–15% of direct maternal 
deaths, with intracranial hemorrhage as the most frequent 
cause. Reducing the occurrence of preeclampsia/eclampsia-
related deaths is an important aspect of one of the World 
Health Organization Millennium Goals: to reduce the mater-
nal mortality ratio by 75% between 1990 and 2015.45,46
In the long-term, preeclampsia among mothers is associ-
ated with an increased risk of developing CVD.47 Indeed, a 
recent systematic analysis estimated that women with a his-
tory of preeclampsia/eclampsia have approximately double 
the risk of early cardiac, cerebrovascular, and peripheral 
arterial disease and cardiovascular mortality compared 
with women without such a history.48 The reasons for this 
increased risk of CVD are unknown, but shared risk factors – 
including endothelial dysfunction, obesity, hypertension, 
hyperglycemia, insulin resistance, and dyslipidemia – have 
led to suggestions that metabolic syndrome may be an under-
lying mechanism common to CVDs and preeclampsia.49 
A recent systematic analysis of observational studies showed 
that women with a history of preeclampsia may also have an 
increased risk of microalbuminuria.50
Children born to pregnancies complicated by preec-
lampsia and intrauterine growth restriction (IUGR) can also 
have long-term sequelae including type 2 diabetes mellitus, 
hypertension, and CVD.51,52 For example, the Helsinki Birth 
Cohort study, which examined 284 pregnancies complicated 
by preeclampsia and 1592 complicated by gestational hyper-
tension, found that people born to mothers with these condi-
tions were at increased risk of stroke (HR: 1.9; P = 0.01).52 
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Mechanisms underlying the effects of preeclampsia and 
IUGR and long-term sequelae have not been elucidated, 
but proposals include fetal undernutrition, genetic suscep-
tibility, and postnatal accelerated growth.53 A potential role 
of epigenetic modifications in the process has also been 
 suggested.51 A recent study comparing normotensive IUGR 
cases vs 31 IUGR cases with preeclampsia suggested that 
IUGR is the key factor affecting cardiac function, rather than 
the preeclampsia itself.54
The role of aspirin in preeclampsia
Causes of preeclampsia are not clear, but it is thought that 
individuals with preeclampsia have an imbalance of pros-
taglandin I2 (PG12) and thromboxane A2 (TXA2), which 
induces a vasoconstriction state. Aspirin is known to inhibit 
TXA2, a potent activator of platelet aggregation and vasocon-
striction, thus reducing the balance between vasoconstriction 
and vasodilation. Findings from RCTs, observational studies 
and meta-analyses indicate that aspirin treatment initiated 
early in pregnancy is an efficient method of reducing the inci-
dence of preeclampsia and its consequences (Table 1);9,10,55–60 
only aspirin and calcium in a low-intake diet have been shown 
to have effects for the prevention of preeclampsia. Heparin or 
dalteparin and aspirin, however, may be superior to aspirin 
alone in women with inherited thrombophilias.55
The most recent meta-analysis, which examined 27 stud-
ies involving 11,348 women, showed that low-dose aspirin 
was effective in reducing preeclampsia (RR: 0.47), severe 
preeclampsia (RR: 0.09), and IUGR (RR: 44) when used in 
early pregnancy (,16 weeks’ gestation) (Figure 2).61–71 These 
findings support the results of earlier studies, including a 
meta-analysis of 14 trials involving 12,416 women, which 
showed that aspirin was beneficial in reducing perinatal death 
and preeclampsia, and increasing birth weight.72 The benefits 
of aspirin in reducing blood pressure in pregnant women may 
also be linked to time of administration, with bedtime admin-
istration being more effective than at other times of day.73 
Findings from the Cochrane group, which have analyzed 59 
trials to date (37,560 women), also suggest that the benefits of 
aspirin are greater in women at high risk of developing preec-
lampsia compared with low-risk women.10 It may be important 
to develop a risk–benefit threshold in pregnant women based 
on risk factors for preeclampsia, safety issues (such as previ-
ous GI ulcers, Helicobacter pylori infection, etc), aspirin dose 
and timing, and duration of treatment. Preeclampsia could also 
be used to predict future increased risk of CVD, particularly 
hypertension, later in life,74,75 and could be introduced into 
risk calculation scores for women.
Despite the data supporting the use of aspirin in high-risk 
pregnancy, considerable variation in its use for this condi-
tion is observed.22 To date, there are no accurate tests that 
are suitable for use in routine clinical practice to predict the 
likelihood of preeclampsia in women not at high risk.76
Prevention of miscarriage in women  
with antiphospholipid syndrome
The antiphospholipid syndrome can lead to thrombosis, 
pregnancy loss, and pre-term delivery, particularly in 
patients with preeclampsia.77 It has been postulated that a 
procoagulant state is induced in the antiphospholipid 
syndrome, which is mediated by TXA2 (Figure 3).77 
Reduction of this thrombogenic state could explain the ben-
efits associated with aspirin use in these patients. A number 
of studies (summarized in Table 2)78–85 have demonstrated 
that aspirin, either alone or in combination with heparin, 
prevents recurrent miscarriage in patients with antiphos-
pholipid antibodies (APLAs); these studies suggest that 
aspirin plus unfractionated heparin is associated with better 
outcomes than aspirin alone or aspirin plus low-molecular-
weight heparin.
Based on these findings, the American College of Chest 
Physicians guidelines recommend aspirin plus heparin 
(unfractionated or low molecular weight) in pregnant patients 
with APLAs and a history of more than two early pregnancy 
losses or more than one late pregnancy loss, preeclampsia, 
IUGR, or abruption.86 Aspirin in combination with heparin is 
also recommended in pregnant individuals without recurrent 
miscarriage and/or fetal loss if they are positive for APLAs 
and have a history of thromboembolism (Table 3).77
Prevention in women with idiopathic 
recurrent miscarriage
Recurrent miscarriage ($3 consecutive losses , 20 weeks 
postmenstruation) is a distressing problem that can affect as 
many as 0.5%–3% of fertile couples of reproductive age.87 
In many cases, no underlying cause (such as antiphospho-
lipid syndrome) can be identified, and there is currently no 
treatment for this problem. A recently completed prospec-
tive study comparing patients with unexplained recurrent 
first-trimester pregnancy loss with matched control subjects 
found that those with unexplained recurrent miscarriage 
have significantly increased platelet aggregation in response 
to arachidonic acid.87 The enhanced response to this ago-
nist provides a strong rationale for the use of aspirin in 
management of this clinical condition. Small-scale trials 
investigating the use of aspirin in the prevention of recurrent 
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miscarriage in women without antiphospholipid syndrome 
have so far found little benefit;88 however, the findings 
regarding aggregation response to arachidonic acid lend 
support to reevaluating the benefit of aspirin in larger trials 
with a clearly defined cohort of individuals with recurrent 
miscarriage.
The expanding role of aspirin  
in chronic inflammatory disorders
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) – an inﬂammatory 
rheumatic disease of immunologic origin characterized 
by autoantibody production, polyarthritis, and protean 
clinical manifestations – affects considerably more women 
than men.89 Cardiovascular morbidity and mortality is a 
frequent complication of SLE, particularly in females aged 
35–44 years, in whom the risk of MI is raised 50-fold.90 
Traditional cardiac risk factors – including hyperlipidemia, 
hypertension, and sedentary lifestyle – are all prevalent 
in patients with SLE, but cannot fully account for the 
 magnitude of this increased risk, suggesting that SLE itself 
may also confer increased risk.91 Conventional wisdom 
in the field is that cardiac risk factors should be aggres-
sively treated in SLE, although there are limited data on 
the effectiveness of individual interventions. The benefits 
observed with aspirin in the reduction of cardiovascular 
events in non-SLE populations suggest that it may also 
benefit women affected by the condition, although further 
investigation is warranted; however, as APLAs may also 
be involved in the development of SLE, it is likely that 
aspirin could prevent the thrombogenic state, as described 
previously.77
The potential role of aspirin  
in cancer
The potential role of aspirin in cancer prevention is based 
on more than 30 years of research, with beneficial effects 
being mainly observed in colorectal adenoma and cancer 
Figure 2 The effect of aspirin treatment on preeclampsia (A) and IUGR (B) in pregnant women (#16 weeks’ gestation). Adapted with permission from Bujold E, et al. 
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy Obstet Gynecol. 2010;116:402–414, with permission from LWW.
Abbreviations: CI, confidence interval; df, degrees of freedom; IUGR, intrauterine growth restriction; M-H, Mantel-Haentszel.61–71
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 prevention.7 Aspirin may exert its beneficial anticancer effects 
through inhibition of cyclooxygenase (COX)-1 in platelets or 
COX-1 and/or COX-2 in nucleated cells.92 This will result in 
the inhibition of COX-derived products that are involved in 
angiogenesis (TXA2) or apoptosis (PGE2/PGE2 receptors). 
Non-COX-dependent pathways may include modulation of 
oncogenic factors (eg, NFκB), other pathways (eg, β-catenin), 
genetic alterations (eg, DNA), or energy depletion of tumor 
cells by phosphorylation.93
Colorectal cancer
Colorectal cancer is a serious concern among both men and 
women. It is estimated that in 2010, there will be 102,900 
new cases of colorectal cancer (49,470 in men and 53,430 in 
women) and 39,670 new cases of rectal cancer (22,620 in 
men and 17,050 in women).94 A recent analysis of  studies 
in primary and secondary prevention of vascular events, 
involving . 14,000 patients, found that low-dose aspirin 
(75 mg/day) reduced the long-term incidence and mortality 
due to colorectal cancer.6 In this analysis, the reductions in 
incidence and death due to colorectal cancer were greater 
for proximal colon tumors than for distal colon or rectal 
tumors. This is an important finding, as regular screening with 
sigmoidoscopy or colonoscopy is not effective in preventing 
tumors in this location.6 A further study using participants 
from the NHS (n = 83,767) showed that aspirin use was asso-
ciated with 29% reduction in the risk of colorectal cancer in 
women.95
Breast cancer
Breast cancer is a signif icant concern among many 
women. In the US in 2006, breast cancer claimed the 
lives of 40,821 females.23 Nonsteroidal anti-inﬂammatory 
drugs (NSAIDs), including aspirin, inhibit COX and 
thereby reduce prostaglandin synthesis. The observation 
that abnormally upregulated COX and prostaglandins 
Inhibitory effects of aspirin
Interaction with coagulation-regulatory
proteins (protein C, prothrombin, plasmin)
Expression of adhesion
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Endothelial cell Monocyte Platelets
Upregulation of tissue
factor production
Upregulation of tissue
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A2 production
Complement activation
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Figure 3 Pathogenesis of thrombosis in antiphospholipid syndrome and the mode of action of aspirin and heparin.77 
Adapted from The Lancet, Published online September 6, 2010, Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Copyright (2011), 
with permission from elsevier.
Abbreviation: LMWH, low-molecular-weight heparin.
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are  features of breast cancer suggests that aspirin may have 
potential value in treatment and prevention of the disease. 
Results investigating effects of aspirin on incidence of breast 
cancer are inconsistent, with some studies identifying reduced 
incidence of breast cancer in women taking aspirin vs those 
not taking aspirin, and others finding no effect (Table 4);96–103 
given this lack of consistent findings, further investigation is 
warranted. A recent prospective observational study based 
on responses from 4164 female registered nurses in the NHS 
who were diagnosed with stages I–III breast cancer has indi-
cated that among women living $ 1 year after a breast cancer 
diagnosis, aspirin use was associated with a decreased risk 
of distant recurrence and breast cancer death.96
endometrial cancer
Although no prospective studies to date have explored the 
relationship between the use of aspirin, other NSAIDs, and 
acetaminophen and endometrial adenocarcinoma, data from 
a prospective cohort study suggest that while use of aspirin 
or other NSAIDs do not play important roles in endometrial 
cancer risk overall, risk is significantly lower for current aspi-
rin users who are obese or who were postmenopausal and had 
never used postmenopausal hormones.104 The potential effects 
of aspirin in these subgroups warrant further investigation.
Table 3 Suggested treatment regimens (involving aspirin) for 
conditions associated with antiphospholipid syndrome77
Patient Treatment (primary  
thromboprophylaxis)
Patients with systemic lupus  
erythematosus and lupus  
anticoagulant and/or persistently  
positive anticardiolipin
Hydroxychloroquine and  
consider low-dose aspirin
Patients with obstetric  
antiphospholipid syndrome  
(outside pregnancy)
Low-dose aspirin or no therapy
Asymptomatic carriers  
of antiphospholipid antibodies
No therapy or low-dose aspirin
Pregnant patient Treatment (prophylactic  
or therapeutic)
Antiphospholipid syndrome  
without previous thrombosis and  
with recurrent early miscarriage
Low-dose aspirin alone or  
with unfractionated heparin
Antiphospholipid syndrome without  
previous thrombosis and with fetal  
death ($10 weeks’ gestation) or  
severe early-onset preeclampsia
Low-dose aspirin plus  
unfractionated heparin  
or LMWH
Antiphospholipid syndrome with  
previous thrombosis
Low-dose aspirin plus  
unfractionated heparin  
or LMWH
Adapted from The Lancet, Published online September 6, 2010, Ruiz-Irastorza G, 
Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Copyright 
(2011), with permission from elsevier.
Abbreviation: LMWH, low-molecular-weight heparin.
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Conclusion
Aspirin has a clear role in the secondary prevention of CVD 
in individuals. Although initial trials with aspirin had limited 
representation of women, subsequent large-scale, long-term 
studies have confirmed the relevance of the findings in women. 
RCTs and cohort studies show that aspirin is also consistent 
in reducing the risk of first events in appropriate patients and 
support the benefit–risk profile of aspirin in primary prevention. 
Beyond CVD, however, aspirin may provide additional benefits 
in women. Numerous trials have indicated the benefits of aspirin 
for preeclampsia, in reducing IUGR, and in preventing miscar-
riage in pregnant women with APLAs. Trials also suggest that 
there may be benefits for individuals diagnosed with breast 
cancer, although these findings require confirmation in larger, 
long-term studies. The low rates of uptake of aspirin among 
women in whom it is indicated remains a concern given the 
role of CVD in death among women. Reasons why women are 
less likely to have been prescribed aspirin have not been estab-
lished, but the overall underuse of aspirin in women needs to be 
addressed. Although aspirin use in women is recommended in 
a number of CVD prevention guidelines, it is possible that the 
development of more extensive guidelines specific to women’s 
issues could address some of these concerns. A number of 
ongoing trials are looking at the role of aspirin in women only 
studies; these include breast cancer (in women on tamoxifen 
therapy), in preeclampsia (in combination with enoxaparin or 
progesterone), and in recurrent miscarriage (in combination 
with folic acid, steroids, or heparin).
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